NETRI develops human cell-based assays and organs-on-chip technologies that utilize neurons as biosensors to evaluate acute and chronic responses in pharmaceutical research. By providing high-throughput electrophysiological recording and AI-driven predictive analytics, NETRI enhances drug discovery and preclinical testing across various therapeutic areas, including oncology and neurological disorders.
Funding
$5.4K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of evaluating the safety and efficacy of pharmaceutical compounds and other products rely on animal testing or simplified in vitro models that do not fully replicate human physiology. This can lead to inaccurate predictions of clinical outcomes, resulting in costly failures in drug development and potential risks to human health.
Solution
NETRI develops advanced human cell-based assays and organs-on-chip platforms that utilize neurons as biosensors to provide more accurate and predictive preclinical data. Their NeuroFluidics™ technology enables the creation of innervated, multi-organ models that mimic human physiology, allowing for high-throughput electrophysiological recording and AI-driven analysis of compound effects. By integrating human stem cell-derived neurons into microfluidic devices, NETRI's platforms offer a unique approach to assessing toxicity, efficacy, and mechanisms of action across various therapeutic areas, including oncology, neurology, and dermo-cosmetics. The company's services include running sprint tests to predict clinical outcomes, co-developing new models, and out-licensing technology to integrate into existing drug development pipelines.
Target Audience
NETRI's primary customers are pharmaceutical, nutrition, and dermo-cosmetics companies seeking advanced preclinical testing solutions to improve drug discovery, assess product safety, and predict clinical outcomes.
Features
- Organs-on-chip platforms with integrated human stem cell-derived neurons for enhanced physiological relevance
- High-throughput microfluidic devices compatible with multi-electrode array (MEA) technology for electrophysiological recordings
- Compartmentalized MEA metrics extracted with NETRI UpLink® from recordings
- Digital Signature Library of reference compounds aggregated in n-dimensional signature clusters
- AI-driven predictive analytics to translate preclinical data into clinical outcomes
- Customizable models for various applications, including neurotoxicity, pain, and inflammation
- Ability to co-culture multiple cell types, including neurons, keratinocytes, and endothelial cells
- Platforms for recreating specific disease conditions, such as atopic dermatitis and chemotherapy-induced peripheral neuropathy